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ABSTRACT
Objectives: PTEN hamartoma tumor syndrome 
(PHTS) is a hereditary disorder caused by germline 
inactivating mutations of the PTEN gene. PHTS includes 
Cowden syndrome and Bannayan-Riley-Ruvalcaba 
syndrome. We describe how the peculiar pathologic and 
immunohistochemical thyroid features lead pathologists to 
suggest PHTS.
Methods: A 28-year-old white Spanish woman had a 
multinodular goiter. Total thyroidectomy was performed 
after fine-needle aspiration biopsy. Microscopic, 
immunohistochemical, and molecular analyses of the thyroid 
lesions were realized. 
Results: The thyroid was multinodular, showing one 
papillary microcarcinoma, five follicular adenomas, 
three adenolipomas, 46 tiny adenomatous nodules 
(microadenomas), scattered foci of adipose tissue, 
and lymphocytic thyroiditis. Tumors were positive for 
thyroglobulin, thyroperoxidase, pendrin, cyclin D1, and 
p27 but negative for calcitonin and PTEN. A germline 
heterozygous deletion of one adenine at nucleotide 827 in 
exon 8 of the PTEN gene was confirmed. No BRAF, NRAS, 
or KRAS somatic mutations were detected in the papillary 
microcarcinoma, follicular adenoma, adenolipomas, or 
microadenomas. Negativity for PTEN was also found 
in the colonic tubulovillous adenoma and the storiform 
collagenoma.
Conclusions: Pathologists play a crucial role in recognizing 
pathologic thyroid findings associated with PHTS for 
selecting patients for genetic testing.
Phosphatase and tensin homolog (PTEN) hamartoma 
tumor syndrome (PHTS) is a rare, autosomal dominant spec-
trum of disorders caused by germline inactivating mutations 
in the PTEN tumor suppressor gene located on 10q23.3. 
PHTS includes Cowden syndrome (CS), presenting in adult-
hood; Bannayan-Riley-Ruvalcaba syndrome (BRRS) in 
children; adult Lhermitte-Duclos disease; and autism spec-
trum disorders associated with macrocephaly.1,2
Individuals with germline PTEN mutations have an 
increased risk of breast, thyroid, endometrium, colorectum, 
and kidney cancer and melanoma.3 Diagnostic criteria for 
CS were initially proposed in 1983.4 The National Compre-
hensive Cancer Network developed testing criteria to estab-
lish when PTEN testing is indicated, based on the clinical 
profile,5 and a new set of PHTS diagnostic criteria1 has been 
recently proposed, with molecular testing recommended, to 
confirm a clinical diagnosis and facilitate testing of at-risk 
relatives.
Upon completion of this activity you will be able to:
•	 recognize the characteristic pathologic thyroid findings of patients 
with PTEN hamartoma tumor syndrome (PHTS).
•	apply immunohistochemistry for PTEN protein in the thyroid gland to 
confirm the possibility of PHTS.
•	 list the malignant tumors with elevated incidence in individuals 
with PHTS. 
The ASCP is accredited by the Accreditation Council for Continuing 
Medical Education to provide continuing medical education for physicians. 
The ASCP designates this journal-based CME activity for a maximum of 
1 AMA PRA Category 1 Credit ™ per article. Physicians should claim only 
the credit commensurate with the extent of their participation in the activ-
ity. This activity qualifies as an American Board of Pathology Maintenance 
of Certification Part II Self-Assessment Module.
The authors of this article and the planning committee members and staff 
have no relevant financial relationships with commercial interests to disclose.
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Thyroid pathologic findings in patients with CS are 
distinctive and characteristic,6,7 and the same peculiar thy-
roid pathology findings have been detected in patients with 
BRRS.7,8 Interestingly, because negativity for PTEN protein 
immunostaining seems to be sensitive and specific for CS,9 
thyroid pathologists are strategically placed to alert clini-
cians to the possibility of PHTS.
This present study describes the peculiar pathologic 
and immunohistochemical thyroid features that have led us 
to suggest a diagnosis of PHTS, which was eventually con-
firmed genetically.
Clinical History
A 28-year-old white Spanish woman was admitted to 
the hospital with a multinodular goiter. She has a history 
of acral keratoses and lipoma in the neck; two melanocytic 
nevi in the skin of the neck and abdominal wall were also 
removed at 5 and 20 years of age, respectively. No history 
of radiation exposure or family history of goiter or other 
disorders was noted. Routine laboratory test results were 
within normal limits. Total thyroidectomy was performed 
after fine-needle aspiration biopsy of the main nodule in the 
right thyroid lobe indicated follicular neoplasm (class IV, 
Bethesda system).
Following the pathologic thyroid findings and the molec-
ular genetic analysis, a workup was carried out, revealing 
gingival papillomatosis, one oncocytoma in the left kidney, 
a calcified right breast fibroadenoma, three hepatic heman-
giomas, and cholelithiasis. Esophageal glycogenic acanthosis, 
one gastric hamartomatous polyp, one ileal lipoma, and two 
ganglioneuromatous polyps as well as two juvenile polyps in 
the large bowel were also detected. In the following years, 
subsequent endoscopic screening and polypectomies yielded 
one endometrial polyp, one esophageal squamous papilloma, 
and multiple gastric and duodenal hamartomatous polyps; in 
the large bowel, multiple ganglioneuromatous polyps, one 
inflammatory polyp, one serrated adenoma, and one tubulo-
villous adenoma were found as well. Two cutaneous storiform 
collagenomas in the wrist and right thigh were also diagnosed, 
along with two peculiar unencapsulated vascular lesions in 
both legs, admixtured with adipocytic and fibrous tissues, 
which have recently been referred to as PTEN hamartoma of 
soft tissue.10 At present, 7 years after the thyroidectomy, the 
patient is alive and well.
Materials and Methods
The thyroidectomy specimen was fixed in neutral, 
phosphate-buffered, 10% formalin and included in paraffin 
blocks. Paraffin-embedded sections were stained with H&E, 
and the immunohistochemical studies were also performed 
on 4-μm–thick paraffin sections using a peroxidase-con-
jugated labeled dextran polymer (EnVision FLEX/HRP; 
Dako, Glostrup, Denmark), with 3,3′-diaminobenzidine 
as the chromogen. The primary antibodies were used 
as follows: thyroglobulin (polyclonal, ready to use, low 
pH; Dako), thyroperoxidase (MoAb47, dilution 1:50, high 
pH; Dako), pendrin (UIRF 01065, 1:500; MBL, Nana-ku 
Nagoya, Japan), calcitonin (polyclonal, ready to use, high 
pH; Dako), cyclin D1 (EP12, ready to use, high pH; Dako), 
p27 (1B4, prediluted, high pH; Novocastra, Newcastle Upon 
Tyne, UK), and PTEN protein (clone 6H2.1, 1:50, high pH; 
Dako). Nonimmune mouse and rabbit serum samples were 
substituted for the primary antibodies as negative control 
samples. As noted in other studies,9 the vascular endothe-
lium within the tumors served as an internal positive control 
for PTEN.
For molecular genetic analysis, genomic DNA was 
extracted from peripheral blood of the patient; polymerase 
chain reaction (PCR) direct sequencing of the PTEN gene 
with primers targeting all nine exons and flanking introns 
was performed as previously reported.11 DNA samples from 
paraffin sections of one papillary microcarcinoma (mPTC), 
one follicular adenoma, two adenolipomas, and two adeno-
matous nodules (defined as nodules with a microfollicular 
pattern of growth that lack capsules) were also obtained by 
microdissection, using the Leica AS LMD system (Leica 
Microsystems, Wetzlar, Germany). These samples were 
screened for somatic BRAF gene mutations by real-time 
PCR (Cobas 4800 BRAF V600 Mutation Test; Roche 
Diagnostics, San Cugat del Vallés, Spain) and for NRAS 
and KRAS mutations by pyrosequencing (PyroMark Q24; 
Qiagen, Hilden, Germany).
We were also able to investigate the immunohistochem-
ical expression of PTEN protein in the renal oncocytoma, 
one of the storiform collagenomas, the two hamartomatous 
lesions of the soft tissue, the tubulovillous adenoma, and two 
ganglioneuromatous polyps of the large bowel.
Results
Gross, Histologic, and Immunohistochemical Findings
The surgical specimen weighed 37.5 g and measured 
50 × 35 × 27 mm in the right lobe and 35 × 20 × 16 mm 
in the left lobe. The cut surface was multinodular, show-
ing seven well-delimited, solid nodules involving both 
lobes. Microscopically, one mPTC, follicular variant, that 
was 2.5 mm in diameter, with lymphocytic infiltration, 
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or infiltration of the thyroid capsule, was found in the 
isthmus (stage I, pT1 N0 M0) ❚Image 1❚. Five follicular 
adenomas with trabecular and/or microfollicular patterns 
of growth, including oncocytic (Hürthle cell) or clear cells, 
and three adenomas with a mixture of mature fat and fol-
licles (adenolipomas), ranging from 2 to 30 mm in greatest 
diameter, were identified in both lobes (Image 1). At least 
46 tiny adenomatous nodules (so-called microadenomas), 
one with adipose infiltration, were distributed throughout 
the gland. Scattered foci of adipose tissue and multiple 
lymphoid infiltrates with germinal centers (lymphocytic 
thyroiditis) distributed throughout the thyroid parenchyma 
were observed (Image 1). Small foci of follicular cells with 
oncocytic or squamoid change were also identified associ-
ated with some lymphocytic aggregates.
All thyroid tumors were positive for thyroglobulin, thy-
roperoxidase, pendrin, cyclin D1, and p27; no reaction was 
found for calcitonin and PTEN protein (Image 1). Isolated 
calcitonin-positive C cells were found, but no C-cell hyper-
plasia was detected.
Strong immunoreactivity for PTEN protein was 
observed in the renal oncocytoma and ganglioneuromatous 
polyps, very weak staining was found in the hamartomatous 
lesions of the soft tissues, but no reaction was detected in 
the storiform collagenoma or in the tubulovillous adenoma 
❚Image 2❚.
Molecular Findings
Germline mutational analysis of the PTEN gene showed 
a heterozygous deletion of one adenine at nucleotide 827 in 
exon 8 (NM_000314.4(PTEN): c.827delA); this mutation 
creates a frame shift starting at codon Asn276, and the new 
reading frame ends at a stop codon, 14 positions down-
stream (p.Asn276Ilefs*15). However, no BRAF, NRAS, or 




❚Image 1❚ Thyroid pathology in Cowden syndrome. 
Papillary microcarcinoma, follicular variant (A, H&E, ×200). 
Tiny adenomatous nodules (so-called microadenomas), 
with foci of adipose tissue (B, H&E, ×100) and lymphoid 
infiltrates with germinal centers (lymphocytic thyroiditis) (B 
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Discussion
In the present case, the patient had a multinodular goi-
ter, including benign and malignant lesions that were char-
acteristic enough to lead to the diagnosis of PHTS. Harach 
et al6 were the first to note that the histologic findings of 
a multiple adenomatous goiter and/or multiple follicular 
adenomas (including adenolipomas and the so-called micro-
adenomas), particularly in children and young adults, should 
alert to the possibility of an inherited trait, such as CS. More 
recently, the same characteristic multicentric, bilateral, 
adenomatous nodules in a background of lymphocytic thy-
roiditis with benign and/or malignant follicular cell–derived 
neoplasms were confirmed in the thyroids of patients with 
CS7 and BRRS.7,12,13
PHTS is a term that encompasses several clinical 
syndromes such as CS and BRRS, caused by germline 
inactivating mutations of the PTEN tumor suppressor gene. 
According to the criteria at our disposal, we herein described 
a case of PHTS clinically fitting with the diagnosis of CS.1 
Although germline mutations in PIK3CA, AKT1, SDHB, and 
SDHD genes as well as KLLN epimutation have been report-
ed in rare cases of CS and Cowden-like syndrome,12,14,15 a 
germline inactivating mutation of the PTEN gene was con-
firmed in our case.
A recent study confirmed an elevated age-adjusted 
standardized incidence ratio for carcinomas of the breast, 
thyroid, endometrium, colorectum, kidney, and melanoma in 
individuals with PHTS.3 Follicular cell–derived carcinoma is 
a major criterion and an important feature in PHTS.6,7,13,16,17 
Thyroid cancer was reported in 14% of patients with PTEN 
mutation and CS,18 while in patients with PTEN mutation 
(CS and BRRS) and thyroid pathology, it rose to 75%.7 
The main histologic subtypes of thyroid carcinoma were 
papillary carcinoma (60%-80%), follicular carcinoma (14%-




❚Image 1❚ (cont) Loss of PTEN protein expression in follicular 
cells in a follicular adenoma (D, PTEN, ×200) and in one 
adenolipoma (E, PTEN, ×200); normal follicular cells (D) and 
endothelial cells (internal positive control) are positive for 
PTEN (D and E). Adenolipoma also showed positivity for 
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A B
C D
❚Image 2❚ Extrathyroid lesions in Cowden syndrome. Renal oncocytoma (A, H&E, ×400) showing strong positivity for PTEN 
protein (A, inset, ×400). Weak staining for PTEN in the vascular component of one hamartomatous lesion of the soft tissues (B, 
×200). Endoscopic appearance of one ganglioneuromatous polyp (C), which was positive for PTEN in the immunohistochemical 
study (D, PTEN, ×400). Endoscopic image of one tubulovillous adenoma (E) that showed negativity for PTEN in the epithelial 
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(but not medullary carcinoma) was also reported in some 
patients.6,7 This association with benign and malignant fol-
licular tumors can be explained because PTEN downregu-
lates the antiapoptotic/proproliferative AKT (protein kinase 
B) and mitogen-activated kinase (MAPK) pathways, the two 
main pathways involved in progression of thyroid tumori-
genesis.19 In fact, as occurred in the present case, the loss 
of PTEN expression in the adenomatous thyroid nodules, 
whether in all nodules or in a subset of nodules, appears to 
be both sensitive and specific for CS.9
The detection of BRAFV600E mutation in the papillary 
carcinoma of a patient with CS20 suggests the same model 
of tumor progression as in sporadic thyroid tumors. For this 
reason, in our patient, we investigated BRAF, NRAS, and 
KRAS genes (MAPK pathway) in the papillary carcinoma, 
follicular adenoma, adenolipomas, and adenomatous thyroid 
nodules. Despite our negative results, the participation of 
RET/PTC, TRK rearrangement or other less common altera-
tions associated with mPTC could not be excluded.
Pathologists can play a crucial role in the recognition of 
pathologic findings associated with familial nonmedullary 
thyroid cancer.21 The finding of multiple thyroid nodules is 
not unusual, particularly in older people, but these nodules are 
usually heterogeneous hyperplastic nodules combining differ-
ent patterns of growth with colloid nodules, regressive chang-
es (calcification, fibrosis, cystic degeneration, etc), and focal 
lymphocytic infiltration. In PHTS, however, it is precisely the 
combination of multiple, bilateral cellular follicular adeno-
mas, adenomatous nodules, and multiple tiny foci of cellular 
proliferation composed of small follicles lacking abundant 
colloid (the so-called microadenomas), in a background of 
lymphocytic thyroiditis, especially when found in children 
and young adults, that should alert the pathologist to the 
possibility of PHTS. Interestingly, in addition to the peculiar 
pathologic thyroid findings associated with PHTS, there are 
also characteristic thyroid features in familial adenomatous 
polyposis22; in both cases, the morphologic features, along 
with the immunohistochemical findings for PTEN protein 
and b-catenin, respectively, are specific enough to indicate 
genetic testing for the patient.21 The cribriform-morular vari-
ant of papillary thyroid carcinoma is associated with familial 
adenomatous polyposis.21,22 Although the tumors in PHTS are 
usually benign and well demarcated, because of multicentric-
ity and increased risk of recurrence or early progression to 
carcinoma, ultrasound surveillance and total thyroidectomy 
have been recommended.6,13,18
Patients with CS and PTEN mutation have a higher 
frequency of upper gastrointestinal polyps than previously 
believed,23 and they are also prone to developing upper 
and lower polyps and cancer.23-26 As this case exemplified, 
patients with PHTS have a high prevalence of colon polyposis 
with multiple histologic types of polyps such as hyperplastic, 
adenomatous, hamartomatous, lipomatous, ganglioneuroma-
tous, and inflammatory.24,26 To our knowledge, there are no 
studies concerning the immunohistochemical expression of 
PTEN protein in extrathyroidal lesions of patients with PHTS, 
and we believe the potential diagnostic usefulness of the loss 
of PTEN expression in the storiform collagenoma and tubu-
lovillous adenoma in the present case deserves consideration.
To summarize, we present the case of a 28-year-old 
woman in whom a characteristic presence in the thyroid 
gland of multiple, bilateral, follicular adenomas (and adeno-
lipomas), with several adenomatous nodules, including 
the so-called microadenomas, foci of adipose infiltration, 
mPTC, and lymphocytic thyroiditis, has led us to suspect 
CS. Immunohistochemical negativity for PTEN protein in 
the thyroid tumors supported the diagnosis, and this disorder 
was confirmed through genetic testing for the PTEN gene.
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